MENU
+Compare
ASND
Stock ticker: NASDAQ
AS OF
May 30 closing price
Price
$162.84
Change
-$0.73 (-0.45%)
Capitalization
9.85B

ASND Ascendis Pharma A/S Forecast, Technical & Fundamental Analysis

Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients... Show more

Industry: #Biotechnology
ASND
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for ASND with price predictions
May 30, 2025

Aroon Indicator for ASND shows an upward move is likely

ASND's Aroon Indicator triggered a bullish signal on May 13, 2025. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 116 similar instances where the Aroon Indicator showed a similar pattern. In of the 116 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on May 29, 2025. You may want to consider a long position or call options on ASND as a result. In of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for ASND just turned positive on May 30, 2025. Looking at past instances where ASND's MACD turned positive, the stock continued to rise in of 55 cases over the following month. The odds of a continued upward trend are .

ASND moved above its 50-day moving average on May 28, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for ASND crossed bullishly above the 50-day moving average on May 23, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 22 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ASND advanced for three days, in of 276 cases, the price rose further within the following month. The odds of a continued upward trend are .

ASND may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The 10-day RSI Indicator for ASND moved out of overbought territory on May 01, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 21 similar instances where the indicator moved out of overbought territory. In of the 21 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ASND declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ASND’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ASND’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (16.282). P/E Ratio (0.000) is within average values for comparable stocks, (59.459). ASND's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.224). Dividend Yield (0.000) settles around the average of (0.039) among similar stocks. P/S Ratio (23.095) is also within normal values, averaging (270.467).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
ASND
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

ASND is expected to report earnings to fall 13.92% to -136 cents per share on September 09

Ascendis Pharma A/S ASND Stock Earnings Reports
Q2'25
Est.
$-1.36
Q1'25
Missed
by $0.11
Q4'24
Beat
by $0.34
Q3'24
Missed
by $0.18
Q2'24
Missed
by $0.45
The last earnings report on May 01 showed earnings per share of -158 cents, missing the estimate of -147 cents. With 470.65K shares outstanding, the current market capitalization sits at 9.85B.
A.I. Advisor
published General Information

General Information

a developer of drug candidates

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
Tuborg Boulevard 12
Phone
+45 70222244
Employees
879
Web
https://www.ascendispharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SSPY79.73-0.48
-0.60%
Stratified LargeCap Index ETF
AVUV88.13-0.53
-0.60%
Avantis US Small Cap Value ETF
LDEM50.72-0.70
-1.36%
iShares® ESG MSCI EM Leaders ETF
FCG22.02-0.31
-1.39%
First Trust Natural Gas ETF
FBT161.28-2.70
-1.65%
First Trust NYSE Arca Biotech ETF

ASND and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ASND has been loosely correlated with NUVL. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if ASND jumps, then NUVL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ASND
1D Price
Change %
ASND100%
-0.45%
NUVL - ASND
38%
Loosely correlated
-0.20%
ORMP - ASND
37%
Loosely correlated
+4.93%
AMRN - ASND
35%
Loosely correlated
-0.77%
AXON - ASND
34%
Loosely correlated
+2.75%
CASI - ASND
33%
Poorly correlated
+0.53%
More